Influenza Virus Vaccine 2011-2012 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Slides:

Advertisements

Similar presentations

18Feb2009VRBPAC Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Advertisements

Candidate Vaccine Strains and Potency Reagents for Influenza Season

Influenza Vaccine Manufacturing

Candidate Vaccine Strains and Potency Reagents, Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.

Preparation of Reference Influenza Viruses in Mammalian Cells: FDA Perspective Prepared for the Vaccines and Related Biological Products Advisory Committee.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

Vaccines and Related Biological Products

12/2/20041 Modern Methods for Influenza Detection and Sub-typing Ronald Cheshier.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Overview of the Division of Viral Products

H1N1: “Swine Flu”. Why you should care… Every year between 5 and 20% of the population gets the flu. The CDC estimates that the flu kills 36,000 people.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Timothy Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

NS 2 Lipid Bilayer NA (Neuraminidase) HA (Hemagglutinin) M 2 (Ion channel) M 1 (Matrix protein) NP (Nucleocapsid) PB1, PB2, PA (Transcriptase complex)

INTRODUCTION TO INFLUENZA The (Ferret) Sneeze Heard Around The World: The Case Of The Bioengineered Bird Flu Case Study for AAC&U STIRS Project Jill M.

EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global epidemics Influenza viruses.

EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global pandemics Influenza viruses.

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Vaccine Virus Selection W. Zhang 10 Jun 2011 Vientiane WHO WPR and SEAR NIC Meeting Improving influenza vaccine virus selection process - report from a.

Influenza Update September 2015

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Food and Drug Administration

Influenza Today Joseph Mester, Ph.D. September 24, 2009.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

The Current Season: A Review of the Influenza Season Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers.

FLU. Orthomyxoviridae Eight segmented pieces of RNA, a structure that permits the introduction of new RNA. This is called genetic reassortment. This.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Pandemic Influenza A (H1N1) Virology Update Nancy Cox, PhD Alexander.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE USPHS INFLUENZA VIRUS VACCINE STRAIN SELECTION

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group One: Influenza Virulence and Antigenic.

Antigenic Shift v. Drift in Avian and Mammalian Sino- Influenza Type A Viruses. By Charles Hauser, St. Edward’s University Mark Maloney, Spelman College.

Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.

1 Licensure of Pandemic Influenza Vaccines: Demonstration of Effectiveness Vaccines and Related Biological Products Advisory Committee Meeting February.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Q-Pan H5N1 Vaccine) Manufactured by GlaxoSmithKline Vaccines and Related Biological Products Advisory.

Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza.

Influenza Virus Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products.

Influenza H1N1 Introduction. What is Influenza A H1N1?  Influenza virus  Family Orthomyxoviridae  2 important surface proteins  Haemagglutinin (H)

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Samar Musmar,MD,FAAFP Vice Dean for Clinical Affairs An-Najah National University Faculty of Medicine Head, Medicine and Society Dep. Flu Vaccination in.

The New Influenza A/H1N1 Isabelle Thomas May 28-29, 2009 Brussels,

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

Influenza Branch VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA February 16-17, 2005, Bethesda, MD Nancy COX, Ph.D. WHO COLLABORATING.

Update on Surveillance for Influenza Viruses with Pandemic Potential and Candidate Vaccine Viruses Nancy Cox, PhD CDC.

1 Influenza activity in the Southern Hemisphere Ian Barr WHO CC for Reference & Research on Influenza Melbourne The Melbourne WHO.

Virologia Applicata E.A. Influenza VIROLOGIA. Virologia Applicata E.A. Influenza The virus and its replication.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

“Neutralizing Antibodies Derived from the B Cells of 1918 Influenza Pandemic Survivors” (Yu et. al) Daniel Greenberg.

Lisa Grohskopf, MD, MPH U.S. Influenza Surveillance Season National Center for Immunization & Respiratory Diseases Influenza Division U.S. Food.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Options for Influenza Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological.

STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH.

Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.

Marketing Authorisation & Yearly Licence of Influenza Vaccines - „Mock-up” & Pre-Pandemic Influenza Vaccines Zsuzsanna Pauliny MD

Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.

Recommended Timeline for Influenza Vaccinations

Influenza Vaccines MedCh 401 Lecture 5 19May06 KL Vadheim Lecture 4.

Planning for Pandemic Influenza

J. -H. Lin, S. -C. Chiu, J. -C. Cheng, H. -W. Chang, K. -L. Hsiao, Y

Presentation transcript:

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director Division of Viral Products/OVRR/CBER/FDA

Purpose of Today’s VRBPAC Committee Discussion Review influenza surveillance and epidemiology data, antigenic characteristics of recent virus isolates, serological responses to current vaccines, and the availability of candidate vaccine strains and reagents Make recommendations for the strains of influenza A (H1N1 and H3N2) and B viruses to be included in influenza vaccines for use in the United States

Considerations for Vaccine Strain Selection Vaccine effectiveness depends on match between the hemagglutinin (HA) and neuraminidase (NA) of the vaccine and the HA/NA of circulating strains of virus Antigenic drift of HA & NA continuous for influenza A and B Antigenic shift to a new HA subtype much less frequent Antibody to HA correlated with vaccine efficacy Timelines for influenza vaccine production are relatively fixed Strain selection in February necessary for availability of vaccine for subsequent northern hemisphere winter (influenza season) Ample vaccine supplies and timely availability depends on several factors that are influenced by strain selection Growth properties of strains (and available reassortants) used for vaccine production Availability of strain specific reagents (inactivated vaccines) to ensure potency of new vaccine

Types of Analyses Used for Vaccine Strain Selection Epidemiology of circulating strains (CDC) Surveillance data from U.S. and around the world Antigenic relationships among contemporary viruses and candidate vaccine strains (CDC/DOD/CBER) Hemagglutination inhibition (HI) tests using post-infection ferret sera HI tests using panels of sera from humans receiving TIV Virus neutralization tests Antigenic cartography Phylogenetic analyses of HA and NA genes Vaccine effectiveness Manufacturing considerations (CBER/vaccine manufacturers) Availability and characteristics of vaccine strains and high-growth reassortants Availability of potency reagents for inactivated vaccines

Review of the Influenza Vaccine Strain Selection Process VRBPAC strain selection – 2/22/2010 Committee recommended the following strains for inclusion in U.S trivalent influenza vaccines A/California/7/2009 (H1N1)-like virus change from the vaccine recommended A/Brisbane/59/2007 (H1N1)-like virus following emergence of novel H1N1 during 2009 A/Perth/16/2009 (H3N2)-like virus change from the vaccine recommended A/Brisbane/10/2007 (H3N2)-like virus B/Brisbane/60/2008-like virus (B/Victoria lineage) no change from vaccine recommendation

WHO Recommendations for Influenza Vaccine Composition Northern Hemisphere: “It is recommended that the following viruses be used for influenza vaccines in the influenza season (northern hemisphere winter): an A/California/7/2009 (H1N1)-like virus an A/Perth/16/2009 (H3N2)-like virus a B/Brisbane/60/2008-like virus” “As in previous years, national or regional control authorities approve the composition and formulation of vaccines used in each country” VRBPAC and CBER for the U.S.

Committee Discussion Which influenza strains should be recommended for the antigenic composition of the influenza virus vaccine in the U.S.? Data to be considered includes: the epidemiology of circulating influenza viruses the antigenic characteristics of influenza virus strains currently circulating in human populations the serologic responses to circulating influenza viruses of persons immunized with current influenza virus vaccines manufacturing considerations including the availability of suitable vaccine candidate strains

Options for Strain Composition for Influenza Vaccines Influenza A (H1N1) Retain current vaccine strain A/California/7/2009 (H1N1)-like virus Replace current vaccine strain with an alternative vaccine virus Candidates? Influenza A (H3N2) Retain current vaccine strain A/Perth/16/2009 (H3N2)-like virus Replace current vaccine strain with an alternative vaccine virus Candidates? Influenza B Retain current B/Brisbane/60/2008-like virus (B/Victoria lineage) Replace current vaccine strain with alternative vaccine strain (e.g., B/Yamagata lineage) Candidates?